Inhaled Insulin for the Treatment of Type 2 Diabetes

In October 18, 2007, Pfizer, Inc. (New York, NY, USA) ceased marketing of Exubera due to lack of patient and physician acceptance. This report was completed and published prior to that action.

This report examines inhaled insulin for type 2 diabetes. A separate Evidence Report examines inhaled insulin for type 1 diabetes. In this report, we examine the evidence on inhaled insulin for two sub-populations of type 2 diabetes patients: those currently taking insulin and those not currently taking any insulin. We address seven key questions pertaining to...